Comparative Pharmacology
Head-to-head clinical analysis: MOXATAG versus QUIXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOXATAG versus QUIXIN.
MOXATAG vs QUIXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin (extended-release) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors, leading to cell lysis and death via activation of autolytic enzymes.
Quixin (levofloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
775 mg orally once daily for 7 days.
One to two drops in affected eye(s) every 2 hours while awake, up to 8 times daily for 7-14 days.
None Documented
None Documented
The terminal elimination half-life is 1.0–1.5 hours in healthy adults; however, with the extended-release formulation (Moxatag), the effective half-life is prolonged to support once-daily dosing.
Terminal elimination half-life: 6–8 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours if CrCl <30 mL/min).
Approximately 60% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 20% is excreted in feces via biliary elimination.
Renal (approximately 70% unchanged in urine); biliary/fecal (~30%, partly as metabolites and unchanged drug).
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic